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Abstract
Background: Tuberculosis is classified as either pulmonary or extra-pulmonary (EPTB). While much focus has been
paid to pulmonary tuberculosis, EPTB has received scant attention. Moreover, EPTB is viewed as one wastebasket
diagnosis, as “the other” which is not pulmonary.
Methods: This is a retrospective cohort study of all patients treated for EPTB in the state of Texas between January
2000 and December 2005, who had no pulmonary disease. Clinical and epidemiological factors were abstracted
from electronic records of the Report of Verified Case of Tuberculosis. The long-term outcome, which is death by
December 2011, was established using the Social Security Administration Death Master File database. Survival in
EPTB patients was compared to those with latent tuberculosis, as well as between different types of EPTB, using
Cox proportional hazard models. A hybrid of the machine learning method of classification and regression tree
analyses and standard regression models was used to identify high-order interactions and clinical factors predictive
of long-term all-cause mortality.
Results: Four hundred and thirty eight patients met study criteria; the median study follow-up period for the cohort
was 7.8 (inter-quartile range 6.0-10.1) years. The overall all-cause mortality rate was 0.025 (95% confidence interval
[CI]: 0.021-0.030) per 100 person-year of follow-up. The significant predictors of poor long-term outcome were age
(hazard ratio [HR] for each year of age-at-diagnosis was 1.05 [CI: 1.04-1.06], treatment duration, type of EPTB and
HIV-infection (HR = 2.16; CI: 1.22, 3.83). Mortality in genitourinary tuberculosis was no different from latent tuberculosis,
while meningitis had the poorest long-term outcome of 46.2%. Compared to meningitis the HR for death was 0.50
(CI: 0.27-0.91) for lymphatic disease, 0.42 (CI: 0.21-0.81) for bone/joint disease, and 0.59 (CI: 0.27-1.31) for peritonitis. The
relationship between mortality and therapy duration for each type of EPTB was a unique “V” shaped curve, with the
lowest mortality observed at different therapy durations for each, beyond which mortality increased.
Conclusions: EPTB is comprised of several different diseases with different outcomes and durations of therapy. The “V”
shaped relationship between therapy duration and outcome leads to the hypothesis that longer duration of therapy
may lead to higher patient mortality.
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Background
Tuberculosis (TB) affects 8.7 million people each year;
while 1 in every 3 human beings on earth has been exposed
to Mycobacterium tuberculosis and has latent tuberculosis
infection [1]. The vast majority of research on tuberculosis
has focused on pulmonary disease, with efforts to shorten
therapy duration. Meanwhile, the rate of “extra-pulmonary”
tuberculosis (EPTB) has increased from one in every 25 TB
patients in 1995 to about one in every five TB patients
in 2002, and one in every three TB patients in 2011 [2,3].
More than 50% of HIV-infected patients with tuberculosis
present with EPTB. Patients using tumor necrosis factor-α
inhibitors for autoimmune diseases have a 4-5 fold increase
in the rate of active tuberculosis compared with non-users,
and have EPTB rates similar to those with AIDS [4]. The
recommended treatment for drug-susceptible EPTB is
with isoniazid, rifampin, ethambutol and pyrazinamide for
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6 months, with the exception of tuberculous meningitis
which is treated with 9 to 12 months of therapy [5]. In
general, extra-pulmonary tuberculosis in adult patients
has been lumped aside in a wastebasket category. Menin-
gitis is a notable exception [6-10]. Dutt, Moers and Stead
studied the outcomes over an average period of 3 years
post treatment in 219 EPTB the early 1980s [11]. However,
this cohort of patients was treated with a regimen of iso-
niazid and rifampin alone, not the standard four drug regi-
men used today. In a second study, Kwara et al examined
data on 126 patients with EPTB at the dawn of the AIDS
pandemic, and found that the short-term mortality during
treatment of EPTB was associated with HIV-infection,
meningeal tuberculosis and disseminated disease [12].
Long-term outcomes were not reported. Thus, the long-
term outcome in EPTB patients “adequately treated” with
the current standard regimen is unknown, so that it is un-
clear if standard short course therapy is effective in redu-
cing long-term mortality. We have developed methods to
use the Texas electronic database to examine long-term
outcomes such as death in tuberculosis patients [6]. This
study is focused on the evaluation of long-term outcomes
in patients with EPTB, and the demographic and therapy
factors predictive of poor long-term outcome.
Methods
Study design
We performed a retrospective cohort study in which all
patients treated for EPTB between January 1st, 2000, and
December 31st, 2005, had records examined for clinical
and epidemiological factors. The main long-term out-
come, which is all-cause mortality by December 31, 2011,
was then established for each patient. We compared all-
cause mortality rates between EPTB and of age-adjusted
Texas population as well as of another comparable cohort
of patients with latent tuberculosis treated during the
same period [13,14]. The latent tuberculosis patient cohort
was previously reported by us [13,14], while the Texas
age-adjusted all-cause population mortality rates are pub-
lished annually by the Centers for Disease Control and
Prevention (CDC) [15].
Study population and setting
All adult patients who were treated for EPTB and recorded
in the electronic State of Texas surveillance database, as de-
fined by CDC’s Report of Verified Case of Tuberculosis
manual were eligible for the study. We excluded persons
≤18 years-old, since pediatric tuberculosis disease is differ-
ent from that in adults [16]. Texas has 254 counties, which
report to the Texas Department of State Health Services.
The Texas Department of State Health Services requires
health care workers to report an active tuberculosis case
within one working day and latent tuberculosis within one
week to the local county health authority. All tuberculosis
patients in Texas are treated using CDC recommended
regimens and the directly observed therapy strategy
(DOTS) [5]. All latent tuberculosis patients are offered free
isoniazid treatments for at least six months [17].
IRB and regulatory permissions
The original study was to identify the effect of factors such
as weight and other covariates on long term mortality out-
come of tuberculosis patients in Texas. The study was
reviewed and approved by the Institutional Review Boards
(IRB) of UT Southwestern Medical Center (IRB# 122008-
020) and the Texas State Department of Human and Health
Services: [(IRB #09-021) Principal Investigator: Ronald Hall].
Definitions and classifications utilized
Tuberculosis case definitions and classification as EPTB
were based on generic definitions included in the Report
of Verified Case of Tuberculosis manual. An episode of
microbiologically proven tuberculosis disease is defined
as: (1) isolation of M. tuberculosis by culture from a clin-
ical specimen, or (2) demonstration of M. tuberculosis in
a clinical specimen by nucleic acid amplification test, or
(3) demonstration of acid-fast bacilli in a clinical speci-
men when a culture has not been or cannot be obtained
or is falsely negative or contaminated. Patients were con-
sidered to have EPTB if radiographic imaging or clinical
samples taken from disease sites were consistent with tu-
berculosis, and/or if clinical assessment was highly suggest-
ive of tuberculosis. EPTB comprised any extra-pulmonary
disease site: lymphatic, bone and/or joint, genitourinary,
meningeal, peritoneal, and unclassified EPTB sites listed as
“other” in the Report of Verified Case of Tuberculosis. For
the purpose of this study, we excluded patients who had
both EPTB and pulmonary tuberculosis, including any
intra-thoracic disease or pleural tuberculosis or miliary tu-
berculosis. Previous anti-tuberculosis therapy refers to pa-
tients who reported receipt of treatment for tuberculosis in
the medical history.
All-cause mortality was chosen as the primary endpoint of
interest since the exact causes of death were not ascertained
for each patient. The dates of when patients started and
stopped therapy are captured in the Report of Verified Case
of Tuberculosis, and the duration of therapy computed using
these dates for all patients in whom therapy was not inter-
rupted, and rounded to the nearest month. Based on pro-
posals in the published literature, we examined the following
categorized therapy durations defined a priori: <6-months,
6-months, 6-10 months and > -10 months [5,11,12]. In
addition, we took an unbiased approach, specified no cat-
egories, and identified cut-off levels based on the data by
employing classification and regression analysis (CART).
Additionally, based on patients’ case completion reports on
follow-up, comparisons were made between patient groups
using “reasons therapy stopped”.
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Database and data collection methods
We performed a retrospective review of all electronic
medical records of tuberculosis patients recorded in the
Report of Verified Cases of Tuberculosis report for the
State of Texas for the years 2000 to 2005. The database in-
cludes epidemiological, demographic, clinical and labora-
tory data. Each case is reviewed and validated at each
administrative level. Each patient’s death was ascertained
by querying the patient’s record against an updated elec-
tronic copy of the Social Security Administration (SSA)
Death Master File database. The US Department of Com-
merce’s National Technical Information Service verifies
records of deaths in the US and administers the SSA
Death Master File database to prevent identity fraud. The
SSA Death Master File database is widely used for various
diseases and population-level studies; its methods are well
validated and it has an accuracy of 93-96% [18-20]. Mor-
tality ascertainment was by “exact matches”, i.e., sharing
locality, demographic factors and period of care, with sub-
ject record between the SSA Death Master File database
and our Texas tuberculosis file, using previously described
methods [6]. Since the SSA Death Master File database
comprises of deceased persons formerly eligible for legal
work authorization, we restricted our analysis to US citi-
zens and legal residents.
Statistical analysis
We employed machine learning models that have high pre-
dictive accuracy in identifying both high-order complexity
non-linear and linear interactions to identify risk factors of
poor long-term outcome in EPTB [21-27]. We did not as-
sume linear interactions between risk factors and clinical
outcomes since most biological processes are inherently
non-linear and their interactions are obviously non-linear.
We decided a priori to employ hybrid models that included
data mining and standard statistical methods. Classification
and regression tree (CART) analyses were performed using
the Salford Predictive Modeling software. The CART mod-
elling approach was used to rank important predictors of
death and to identify complex interaction between predic-
tors, and to identify optimal thresholds for classifying pa-
tients by mortality if a predictor was a continuous variable.
CART, a binary recursive portioning technique, splits pre-
dictors at each node into homogenous groups based on
assigned penalty rules. By employing the GINI coefficient,
the automated software can identify optimal cut-off points
that maximize penalty rules for continuous variables. Most
important variables for the optimal tree are scored and se-
lected then ranked based on the first node (which is also
called the root node). The variable used in the root node is
scored 100%. Ten-fold cross-validation methods were used
to determine the accuracy of model approach. In this
process, the learning database is randomly split into ten
sets, after which CART is run to estimate what the error
rate of a sub-tree would be if you had a test database,
thereby obviating the need for a validation database.
Cox proportional analyses were used to compute mor-
tality hazard rates and to identify independent predictors
of survival among the different patient groups, including
those who had successfully completed therapy. Next, a
comparison of patients’ demographic, clinical and treat-
ment outcomes between major anatomic sites of tubercu-
losis disease (hereby termed EPTB syndromes) was made
using Pearson’s chi-square test and when appropriate
Fischer’s exact tests for categorical data. Age was modeled
both as discrete (for ease of comparison with general popu-
lation survival which is reported in 10-year increments)
and as a continuous variable (for comparison between pa-
tient groups). Otherwise, continuous data was analyzed by
means of Kruskal-Wallis tests for non-normally distributed
data and analysis of variance or Students’ T-tests for other-
wise. Kaplan-Meier plots together with the log-rank test
were used to examine and to compare cumulative sur-
vival between groups. All analyses were two-sided with
p ≤ 0.05 significance levels and were performed using
STATA (College Station, TX) version 12.
Results
There were 9,441 patients diagnosed with tuberculosis
in Texas during the entire study period. Of these 837
(16%) had EPTB, and 438 (52%) fulfilled study criteria
(Figure 1). In 328 (75%) patients the diagnosis was
microbiologically proven. The initial drug regimens used
and reported for all study patients were consistent with
standard CDC recommendations. The patient characteris-
tics are shown in Table 1. Data on patient weight was
missing in many records, and when available not verifi-
able. Thus, although this factor had been one of the sev-
eral that prompted the study, it was not further analyzed.
Homelessness and substance abuse were common social
factors associated with tuberculosis in this cohort (Table 1).
The table shows that patients’ median age significantly dif-
fered across the type of EPTB (p = 0.02). In addition,
EPTB syndrome (i.e., anatomic site of tuberculosis) sig-
nificantly differed by self-identified “race”: 83% of geni-
tourinary system-tuberculosis patients were “white”
while 17% were distributed among the remainder. The
median study follow-up period for the entire patient co-
hort was 7.8 (inter-quartile range: 6.0-10.1) years, and
was not significantly different between major disease
sites (p = 0.11); patients were evenly distributed across
the surveillance period. The median therapy duration
was 8 (interquartile range: 6-11) months. However, ther-
apy duration differed significantly between EPTB syn-
dromes, especially due to the longer duration of therapy
in patients with bone/joint disease (Figure 2).
One hundred twenty-four (28%) patients died during
the observation period. The overall all-cause mortality
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rate was 0.025 (95% confidence interval [CI]: 0.021-
0.030) per 100 person-year of follow-up; 103 (83%) died
within 70.5 months of diagnosis, only 40 (9%) died dur-
ing therapy, 346 (79%) were recorded as having com-
pleted therapy. In the remaining 12% of patients, the
reason for failing to document completion of therapy
was unknown in 30 patients, 14 were lost to follow up,
five moved out of the Texas jurisdiction, and three were
uncooperative with healthcare workers. Thus, further
analysis was confined to the 346 patients with docu-
mented evidence of having completed treatment. Since
life expectancy is higher in women than men, and long-
term survival is affected by age, the long-term survival
in patients with EPTB is shown for different genders and
for different ages in Figure 3.
CART analyses identified age-at-diagnosis (age), ther-
apy duration, EPTB syndrome (i.e., anatomic site of dis-
ease), and HIV-status as significant predictors of
survival. The highest decision node (i.e., root node) ranked
by CART was age, with a cut-off point of 64.5 years.
Altogether 35/70 (50%) patients >64.5 years died versus 36/
376 (13%) patients ≤64.5 years. In patients >64.5 years, the
next and last decision node was treatment duration, with a
cut-off value of 6 months, with survival of 100% in those
with therapy duration ≥6 months versus 43.5% for therapy
duration <6 months. Thus therapy duration was the next
most important predictor of outcome in patients >64.5 years.
On the other hand, for patients ≤ 64.5 years the next deci-
sion node was type of EPTB syndrome, with a split into
those with genitourinary tuberculosis-TB showing 100%
Figure 1 Study enrollment outline.
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survival versus the rest who had an 83.3% survival. Further
down the tree in this younger group of patients, the next
most important node was treatment duration among
patients without genitourinary tuberculosis, with a cut-off
value of 7 months which classified patients into those
treated for ≤7 months who had a higher survival of 90.4%
versus 81% in those treated for longer than 7 months. In
other words, therapy duration versus survival was described
by a “V” shaped response. The predictive accuracy for the
decision tree, in cross-validation in a test sample, was 92%.
Next, we examined if each of the four parameters identi-
fied by CART analyses were also significant when standard
parametric multivariate analysis was utilized, with time-to-
death as an outcome. The analysis confirmed CART find-
ings, and in addition demonstrated that gender was also a
significant risk factor (Table 2). The relationship between
gender and mortality is shown in Figure 4A. As regards to
age, the hazard ratio for each year of age-at-diagnosis versus
time-to-death was 1.05 (CI: 1.04-1.06; p < 0.001). Figure 4B
shows the survival curves of HIV-infected versus non-HIV-
infected among the 280 patients who were tested for HIV.
Table 1 Demographic and clinical characteristics at the time of starting therapy for the 438 study patients
Variable Total Major site of tuberculosis disease p-value












Age (years) 49(18) 47(18) 52(19) 48(17) 43(15) 49(16) 52(19) 0.02
Male 224(51) 76(47) 46(50) 15(63) 31(56) 23(54) 33(54) 0.63
Race 0.02
White 216(49) 73(45) 46(50) 20(83) 24(44) 21(49) 32(53)
Black 213(49) 85(52) 45(49) 3(13) 31(56) 22(51) 27(44)
Other 9(2) 5(3) 1(1) 1(4) 0 0 2(3)
Ethnicity 0.39
Hispanic 123(28) 42(26) 25(27) 11(46) 14(25) 11(26) 20(33)
Non-Hispanic 315(72) 121(74) 67(73) 13(54) 41(75) 32(74) 41(67)
Residence
Jail 29(7) 14(9) 5(5) 1(4) 2(4) 2(5) 5(8) 0.83
Nursing home 18(4) 8(5) 2(2) 1(4) 3(5) 1(2) 3(5) 0.86
Homeless 13(3) 3(2) 1(1) 1(4) 4(7) 1(2) 3(5) 0.19
Substance abuse
Alcohol 48(11) 17(10) 8(9) 2(8) 3(5) 11(26) 7(11) 0.07
Injection 15(3) 4(2) 6(7) 0 1(2) 4(9) 0 0.06
Other non-injection 35(8) 18(11) 5(5) 2(8) 2(4) 5(12) 3(5) 0.33
HIV-infected 93(21) 52(32) 5(5) 1(4) 16(29) 6(14) 13(21) <0.001
Prior TB 15(3) 3(2) 4(4) 3(13) 1(2) 2(5) 2(3) 0.15
Acid-fast bacilli stain 74(17) 37 (23) 11 (12) 6(25) 4(7) 6(14) 10(16) <0.001
Mtb culture 308(70) 131(80) 72(78) 16(67) 22(40) 30(70) 37(61) <0.001
Completion of therapy 0.08
Completed 346(79) 133(82) 74(80) 21(88) 36(65) 33(77) 49(80)
Not completed 53(12) 15(9) 12 (13) 3(13) 8(15) 5(12) 10(16)
Figure 2 Distribution of therapy duration by type of
extrapulmonary TB disease.
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Figure 4C and D show that when the relationship between
EPTB syndrome and time-to-death was examined, genito-
urinary tuberculosis differed significantly from all other
syndromes. When tuberculous meningitis, which had the
sharpest early decline in survival after completion of ther-
apy, was examined as the referent, the mortality also dif-
fered from some of the non-genitourinary tuberculosis
patients (Table 2). Thus, there are 3 significantly different
survival categories, namely (a) patients with genitourinary
tuberculosis who did as well as those with latent tubercu-
losis treated with isoniazid prophylaxis, (b) patients with tu-
berculous meningitis and peritoneal tuberculosis who had
very poor long-term outcomes, and (c) an intermediate
mortality group comprised of bone/joint, lymphatic, and
“other” tuberculosis syndromes.
The relationship between treatment duration and mortal-
ity was examined in greater detail for each EPTB syndrome,
since treatment duration is potentially modifiable. Genito-
urinary tuberculosis was excluded since only one patient
with that diagnosis died. The CART-derived threshold for
treatment duration versus long-term mortality is shown in
Figure 5. It can be seen in Figure 5, that the relationship be-
tween treatment duration for those who completed therapy
versus mortality was a “V” shaped curve. As therapy dur-
ation increased towards the nadir, survival improved to a
maximum at the vertex, after which longer therapy was as-
sociated with worse survival. The nadir of the relationship
is the therapy duration associated with lowest mortality,
which differed between disease syndromes. The therapy
duration associated with lowest mortality was 7 months for
peritoneal tuberculosis, 8 months for meningitis, 9 months
for lymphadenitis, and 10 months for all “other”-tubercu-
losis syndromes.
Discussion and conclusion
The pulmonary system has always been considered the
“seat” of tuberculosis since the early days of systematic
medicine [28-30]. Detailed studies of the metabolic and
biochemical status of M. tuberculosis, as enumerated in
the three population model hypothesis, with direct con-
sequences on therapeutics, have been painstakingly
mapped for pulmonary tuberculosis [29,31-36]. Nothing
of a similar scope has been performed for most “EPTB”.
Our first major finding is that the use of this wastebas-
ket term conceals radically different types of tuberculosis
in terms of long-term outcomes and duration of therapy.
Figure 3 Cross sectional comparison of survival rates between
patients with extrapulmonary TB and controls. (A). Men. (B) Women.
We used two control groups, patients treated for latent tuberculosis, and
the general Texas population during the same time periods.
Table 2 Multivariate analysis of factors associated with
time to death for the study cohort (402 patients) with
available data for the entire follow-up period*
Variable Hazard ratio (95% CI) P-value
Age (years)
18 – 24 Referent
25 – 34 2.75 (0.60, 12.59) 0.19
35 – 44 2.08 (0.46, 9.44) 0.34
45 – 54 2.42 (0.54, 10.85) 0.25
55 – 64 2.02 (0.42, 9.66) 0.38
65 – 74 3.71 (0.77, 17.79) 0.10
>75 7.43 (1.54, 35.93) 0.01
HIV-infected versus non-infected 2.16 (1.22, 3.83) <0.01
Male 1.52 (1.01, 2.72) 0.04
TB disease site
Meningeal Referent
Lymphatic 0.50 (0.27, 0.91) 0.02
Bone/joint 0.42 (0.21, 0.81) 0.01
Peritoneal 0.59 (0.27, 1.31) 0.20
Other sites 0.47 (0.23, 0.97) 0.04
Therapy duration
6-months Referent
<6-months 2.72 (1.34, 5.50) <0.01
7 – 10 months 1.63 (0.85, 3.12) 0.14
>10-months 1.52 (0.75, 3.10) 0.25
*Multivariate regression analysis drops patients with missing variables, so the
final model comprised of 402 instead of 438 patients.
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Lumping these diagnoses together as “EPTB” is no more
useful than lumping Staphylococcus aureus vertebral
osteomyelitis, carbuncles, and brain abscesses as “non-
bacteremic Staphylococcal disease”. We found a high case
fatality rate for some syndromes during the observation
period, despite “adequate” chemotherapy. To put this in
perspective, the 5 year case fatality rate for untreated
pulmonary tuberculosis that is smear negative but culture
positive is 12-15%, while that for sputum positive is 42-
70% [37]. Thus for microbiologically proven and ad-
equately treated meningitis long-term mortality of 46.2%
and 42.6% for peritonitis, long-term outcomes are remin-
iscent of untreated “consumption.” We propose that each
EPTB syndrome is important in its own right, so that each
EPTB syndrome’s pathology, M. tuberculosis physiology,
and various pharmacological factors should be separately
delineated from the others.
It is unclear why TB infection in different organs is
associated with different mortality. This could reflect
the impact of tuberculosis damage on different organs.
An example are the cerebrovascular accidents in tuber-
culous meningitis [38,39]. Alternatively, this could reflect
the differential penetration of antibiotics into different
anatomic sites. Poor penetration would reduce both peak
concentration and 24 hr area under the concentration-
time curve (AUC) to minimum inhibitory concentration
ratios, which are known to correlate with microbial kill
and suppression of acquired drug resistance in pre-clinical
hollow fiber system of tuberculosis studies and in patients
[21,40-44]. As an example, in tuberculous meningitis, the
blood-brain barrier variably and unpredictably decreases
drug levels depending on compartment and drug selected,
with such drugs as rifampin achieving only 2-20% those
achieved in the serum, while isoniazid AUC is 80% that in
serum [10,45,46]. Indeed, when drugs that penetrate well
into the meninges such as quinolones are included, or
Figure 4 Survival curves of patients who had risk factors of higher mortality. (A). Women versus men. (B). Survival curves for HIV-infected
versus non-HIV infected patients. (C). Survival curves of different EPTB syndromes for the entire cohort. (D). Survival curves for different EPTB
syndromes for EPTB patients with microbiologically proven disease.
Figure 5 The relationship between treatment duration and
mortality is a “V” shaped curve. CART analysis was used to
identify the treatment duration thresholds associated with long-term
outcome within each EPTB syndrome. For all disease syndromes,
mortality decreased with longer treatment duration until a nadir,
which was the treatment duration associated with lowest proportion
of patients with adverse long-term outcomes. Thereafter, mortality
increased with longer duration of therapy.
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rifampin’s dose is increased so that the AUC is increased,
tuberculous meningitis patients have decreased mortality
[8,10]. Similarly, in bone/joint disease, the percentage of
drug in foci in sclerotic bone is 0-8% for rifampin, 0-6%
for pyrazinamide, and 0-23% for isoniazid [47]. These
drug-concentration scenarios are known to lead to ac-
quired drug resistance and poor efficacy [21,48]. Finally, it
could be that for some syndromes such as meningitis, the
M. tuberculosis genotypes that preferentially cause such
disease are more difficult to kill and have a higher propen-
sity to fail and develop drug resistance [49-52].
A third important finding was that the relationship
between therapy duration for each syndrome versus
outcome as “V” shaped. This implies that there is a
combination therapy duration point associated with the
best long-term outcome, and that therapy duration be-
yond this point leads to poorer survival. Thus, unneces-
sarily long therapy could be harmful to patients. In
studies of antibiotics used to treat other bacterial infec-
tions, it has been suggested that better outcomes occur
with shorter rather than longer duration therapy [53].
However, this is a matter of ongoing debate. In our hol-
low fiber studies, longer duration of isoniazid and pyra-
zinamide therapy was an important driver of acquired
drug resistance by M. tuberculosis [41,42]. Thus, longer
therapy duration than necessary could worsen microbi-
ologic outcomes. Nevertheless, given the retrospective
nature of the data, we cannot definitively ascribe caus-
ation of poor long-term outcomes to the longer therapy
duration. Another possibility is that patients who were
not doing well could have had their therapy duration
extended by clinicians, so that the longer therapy dur-
ation may be an indication of patients who were having
poor outcome rather than being the cause of poor out-
come, a post hoc ergo propter hoc fallacy. These possibil-
ities cannot be teased out in a retrospective study, and
thus causation cannot be ascribed at the present mo-
ment. Our findings should thus be viewed merely as
generating a hypothesis, which must then be tested in
prospective studies.
Our study has several limitations. First, the most im-
portant limitation is the retrospective nature of the design.
Additionally, since the data were routinely collected for
surveillance purposes some data points were missing,
while some could have been entered erroneously. Second,
the study patients’ age distribution was skewed in favor of
an elderly population with naturally higher co-morbid
conditions and consequently poorer long-term survival.
Third, variations in the combinations of anti-tuberculosis
drugs used to treat each patient could affect outcomes,
given comorbid conditions with potential drug interaction,
or regimen changes to accommodate acquired drug resist-
ance, all of which limit interpretation of the data. Fourth, a
more detailed exploration of the factors identified as
associated with overall mortality in treated tuberculosis
patients was precluded by the incompleteness of data in
the Report of Verified Case of Tuberculosis. Finally, in the
current analysis, we chose to use CART analyses. However,
CART is prone to over fitting, and slight changes in dataset
may lead to selection of different predictors. This problem
led to extension of the procedure into random forests,
where instead of the forest instead of a single tree, is grown
[54]. We utilized CART because it is more intuitive to clin-
ical decision making by clinicians, is familiar to clinicians,
and is much easier to interpret. In order to make sure the
predictors chosen by CART were indeed correct and not
due to instability, standard parametric multivariate analysis
was utilized to examine the CART-derived predictors and
thresholds, which were all found to be statistically
significant.
In summary, different EPTB syndromes have different
long-term outcomes and different therapy durations asso-
ciated with lowest mortality. The long-term outcomes for
such syndromes as peritoneal and meningeal tuberculosis
adequately treated with modern chemotherapy are suffi-
ciently poor as to be indistinguishable from some types of
tuberculosis before the advent of chemotherapy. The dif-
ferent syndromes should not be lumped into single waste-
basket diagnosis of EPTB.
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